Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

Merck KGaA. (9/1/17). "Press Release: Successful Closing of Biosimilars Transaction". Darmstadt.

Region Region Vevey VD
  Country Switzerland
Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 Fresenius (Group)
Product Product DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics)
Index term Index term Merck (DE)–Fresenius: investment, 201704–201709 acquisition €156m upfront + €500m milestones + royalties of Merck biosimilars business in Vaud CH
Persons Person Oschmann, Stefan (Merck (DE) 201604– CEO before Executive Board Member since 2011 before MSD)
  Person 2 Garijo, Belén (Merck (DE) 201310– CEO of Merck Serono before COO sinc 2011 before Sanofi)
     


• Step towards strategic alignment of R&D resources to Healthcare priorities

• Merck and Fresenius entered into supply and services agreements related to the divested business


Merck today announced the completion of the divestment of its Biosimilars business to Fresenius after having received regulatory approvals. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines in oncology, immuno-oncology and immunology.

“The transaction is part of our continued active portfolio management and marks another step in the transformation of Merck into a science and technology company”, said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “We are pleased having achieved the closing of this transaction which will further enable full focus of our R&D resources on well-defined strategic pillars as our Biopharma pipeline continues to deliver”, said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare.

Merck receives an upfront payment of 156 million €, milestone payments of up to 500 million € plus royalties on future product sales, according to the terms agreed. Merck and Fresenius entered into supply and services agreements, which include drug development support and manufacturing services for Biosimilars. The Biosimilars business was part of the Healthcare businesses sector of Merck. It is located in Vevey and Aubonne in Canton de Vaud, Switzerland. The business is developing a Biosimilars portfolio focused on oncology and inflammatory disorders. Following the completion of the transaction both Biosimilars sites continue to operate in Vevey and Aubonne.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Your Contact

Markus Talanow +49 6151 72-7144
Investor Relations +49 6151 72-3321


Frankfurter Strasse 250
64293 Darmstadt · Germany
Hotline +49 6151 72-5000
merckgroup.com

Head Media Relations -62445
Spokesperson: -9591 / -7144 / -6328
Fax +49 6151 72 3138
media.relations@merckgroup.com

   
Record changed: 2017-09-06

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 3 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 40 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px